Search results
Added:
1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more
Added:
1 year ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants…
View more
Added:
5 months ago
AHA Scientific Sessions 2025 - Dr Nils Krüger (Brigham and Women's Hospital, US) joins us to discuss findings from the TIRZSEMA-CVOT (NCT07096063) study, examining real-world cardiovascular outcomes with tirzepatide and semaglutide in patients with type 2 diabetes at cardiovascular risk.This retrospective cohort study utilized three national US claims databases to evaluate over 887,000 patients…
View more
Added:
2 weeks ago
American College of Cardiology Congress 2026 – Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of tirzepatide compared with dulaglutide on expanded cardiorenal outcomes from the SURPASS-CVOT trial (NCT04255433; Eli Lilly and Company).This international, double-blind, randomised, phase III cardiovascular outcomes trial enrolled 13,299 patients aged 40 and…
View more
Added:
6 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT…
View more
Added:
2 weeks ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,…
View more
Benefits of Spironolactone: Win Ratio Analysis of the TOPCAT Trial
Added:
6 months ago
Original Research
Added:
2 years ago
Source:
Radcliffe Cardiology
AUTHOR: Greg GuilloryTwo late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes…
View more
Added:
10 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement…
View more
Added:
1 year ago
AHA Conference 2024 - In this highlights video from AHA 2024, Dr Michelle Kittleson (Cedars-Sinai California Heart Center, US) offers a concise and insightful summary of the most influential late-breaking trials presented at the conference. Dr Kittleson discusses the pivotal studies poised to impact clinical practice and enhance patient outcomes in heart failure care.Trials covered in detail…
View more